1Antithrombotic Trailists' Collaboration. Collaborative recta-analysis of randomized trails of antiplatdet therapy for prevention of death,myocardial infarction, and stroke in high risk patients[J]. BMJ,2002,324(7329) :71 - 86. Erratum in: BMJ,2002,324(7330) :141
2Peters RJG, Mehta SR,Fox KAA, et al. Effects of aspirin dose when used alone or combination with clopidogrol in patients with acute coronary syndromes. Observations from the clopidogrol in unstable angina to prevent recurrent events(cure) study[J]. Circulation, 2003,108 (14) : 1682 - 1686
3Schunemann HJ, Munger H, Brewer S, et al. Methodology for guideline development for the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J]. Chest,2004,126 (3 Suppl) : 174S - 178S
4Cannon CP, CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis ( CAPRIE trial ) [ J ]. Am J Cardiol, 2002 , 90 (7) :760 - 762
5CURE study investigators. The clopidogrel in unstable angina to prevent recurrent events (CURE) trail programme: rationale, design and baseline characteristics including a metaanalysis of the effects of thyenopyridines in vascular disease[J]. Eur Heart J,2000,21(24) : 2033 -2041
6Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained duel oral antiplatelet therapy following percutaneous coronary interventions(CREDO trail) [J]. JAMA, 2002, 288 (19) : 2411 -2420
7Gratsianskii NA. Real Ahemative to Clopidogrel. Results of the JUMBO-TIMI26 Trial[J]. Kardiologiia ,2004, 44(12) : 77 -78
8Westerhout CM, Boersma E. Risk-benefit analysis of platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes[J]. Expert Opin Drug Saf,2003,2 ( 1 ) :49 - 58
9Boersma E, Harrington RA, Moliterno DJ et al.Platelet glycoprorein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinicals trials [ J ]. Lancet, 2002,359(9302) :189 -98. Erratum in: Lancet,2002,359(9323) :2120
10James SK, Siegbahn A, Armstrong P et al. Activation of the inflammation, coagulation, and flbrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin : a GUSTO IV substudy[J].Am Heart J,2004,147(2) :267 -74